Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin A… Read more
Axim Biotechnologies Inc (AXIM) - Total Assets
Latest total assets as of June 2025: $3.22 Million USD
Based on the latest financial reports, Axim Biotechnologies Inc (AXIM) holds total assets worth $3.22 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Axim Biotechnologies Inc - Total Assets Trend (2011–2024)
This chart illustrates how Axim Biotechnologies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Axim Biotechnologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Axim Biotechnologies Inc's total assets of $3.22 Million consist of 0.0% current assets and 100.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $510.00 | 0.0% |
| Inventory | $510.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.20 Million | 92.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Axim Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axim Biotechnologies Inc's current assets represent 0.0% of total assets in 2024, a decrease from 32.0% in 2011.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 32.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 92.0% of total assets, an increase from 68.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 92.8% of total assets.
Axim Biotechnologies Inc Competitors by Total Assets
Key competitors of Axim Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Axim Biotechnologies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Axim Biotechnologies Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Axim Biotechnologies Inc is currently not profitable relative to its asset base.
Axim Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 1.01 |
| Quick Ratio | 0.00 | 0.00 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.20 Million | $ -6.55 Million | $ 15.86K |
Axim Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Axim Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.86 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -16.4% |
| Total Assets | $3.45 Million |
| Market Capitalization | $975.00K USD |
Valuation Analysis
Below Book Valuation: The market values Axim Biotechnologies Inc's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Axim Biotechnologies Inc's assets decreased by 16.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Axim Biotechnologies Inc (2011–2024)
The table below shows the annual total assets of Axim Biotechnologies Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.45 Million | -16.36% |
| 2023-12-31 | $4.12 Million | -2.15% |
| 2022-12-31 | $4.21 Million | -20.88% |
| 2021-12-31 | $5.32 Million | -52.95% |
| 2020-12-31 | $11.31 Million | +568.74% |
| 2019-12-31 | $1.69 Million | -19.02% |
| 2018-12-31 | $2.09 Million | -4.69% |
| 2017-12-31 | $2.19 Million | +51.27% |
| 2016-12-31 | $1.45 Million | +14.87% |
| 2015-12-31 | $1.26 Million | +70.84% |
| 2014-12-31 | $738.46K | +1199.57% |
| 2013-12-31 | $56.82K | -57.22% |
| 2012-12-31 | $132.82K | +83.70% |
| 2011-12-31 | $72.31K | -- |